Surmodics | SRDX - 销售收入

金融业

USD

USD 178.56M

现金及等价物

USD 36.12M

USD 33.03M

USD 81.3M

USD 20.54M

USD 29.55M

股息收益率

0

USD -322K

USD 1.53M

376

EPS每股收益

USD -0.25

股本和储备

USD 118.9M

USD -11.54M

债务利息支出

USD 884K

USD 29.55M

USD 393.5M

USD -11.54M

USD -245.35M

USD -5.65M

普通股股本

USD 716K

386.18

USD -7.51M

USD 29.92M

销售和管理费用

USD 14.58M

USD 15.17M

贸易债权人

USD 2.79M

应收帐款人

USD 23.27M

	销售	更改		日
Abbott	USD 11.46B		90M	2025-12
Align Technology	USD 1.05B		54.3M	2025-12
Anika Therapeutics	USD 26.17M		12.58M	2025-03
Arrowhead Research	USD 264.03M		7.56M	2025-12
Artivion	USD 95.78M		2.24M	2024-09
Baxter International	USD 2.97B		130M	2025-12
Boston Scientific	USD 5.29B		220M	2025-12
EDAP TMS	EUR 13.88M		2.16M	2025-09
Edwards Lifesciences	USD 1.57B		20M	2025-12
Haemonetics	USD 338.97M		11.97M	2025-12
Heron Therapeutics	USD 32.81M		3.21M	2024-09
J&J	USD 24.6B		610M	2025-12
Merit Medical Systems	USD 393.9M		9.7M	2025-12
Mesa Laboratories	USD 62.84M		5.01M	2024-12
Nektar Therapeutics	USD 24.12M		635K	2024-09
Option Care Health	USD 1.47B		30M	2025-12
Stryker	USD 7.2B		1.14B	2025-12
Surmodics	USD 29.92M		96.16M	2024-12
Trinity Biotech	USD 14.31M		1.55M	2025-09